LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives

International Archives of Medicine

Volumn 3, Issue 1, 2010, Pages

  Al Allaf, Faisal A ^a,b   Coutelle, Charles ^b   Waddington, Simon N ^b,c,d   David, Anna L ^d   Harbottle, Richard ^b   Themis, Michael ^b,e  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ADENOVIRUS VECTOR; ANION EXCHANGE RESIN; BILE ACID; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LENTIVIRUS VECTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; NICOTINIC ACID; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; SQUALENE SYNTHASE INHIBITOR; STATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE CONSTRUCT; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LOW FAT DIET; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; WEIGHT REDUCTION;

EID: 78649942440     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-3-36     Document Type: Review

References (218)

1. A receptor-mediated pathway for cholesterol homeostasis. MS Brown JL Goldstein, Science (New York, NY) 1986 232 4746 34 47 10.1126/science.3513311
2. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. SE Leigh AH Foster RA Whittall CS Hubbart SE Humphries, Annals of human genetics 2008 72 Pt 4 485 498 10.1111/j.1469-1809.2008.00436.x 18325082
3. The Leiden Open (source) Variation Database (LOVD). http://www.ucl.ac.uk/ ldlr/Current/
4. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. MAHC Austin RL Zimmern SE Humphries, Am J Epidemiol 2004 160 421 429 10.1093/aje/kwh237 15321838
5. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. GL Vega SM Grundy, The Journal of clinical investigation 1986 78 5 1410 1414 10.1172/JCI112729 3771801
6. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. LF Soria EH Ludwig HR Clarke GL Vega SM Grundy BJ McCarthy, Proceedings of the National Academy of Sciences of the United States of America 1989 86 2 587 591 10.1073/pnas.86.2.587 2563166
7. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. MAHC Austin RL Zimmern SE Humphries, Am J Epidemiol 2004 160 407 420 10.1093/aje/kwh236 15321837
8. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. M Abifadel M Varret JP Rabes D Allard K Ouguerram M Devillers C Cruaud S Benjannet L Wickham D Erlich A Derre L Villeger M Farnier I Beucler E Bruckert J Chambaz B Chanu JM Lecerf G Luc P Moulin J Weissenbach A Prat M Krempf C Junien NG Seidah C Boileau, Nature genetics 2003 34 2 154 156 10.1038/ng1161 12730697 (Pubitemid 36666925)
9. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. AK Soutar RP Naoumova LM Traub, Arteriosclerosis, thrombosis, and vascular biology 2003 23 11 1963 1970 10.1161/01.ATV.0000094410.66558.9A 12958046
10. Mechanisms of disease: genetic causes of familial hypercholesterolemia. AK Soutar RP Naoumova, Nature clinical practice 2007 4 4 214 225 10.1038/ncpcardio0836 17380167
11. Hyperapobetalipoproteinaemia in two families with xanthomas and phytosterolaemia. PO Kwiterovich Jr PS Bachorik HH Smith VA McKusick WE Connor B Teng AD Sniderman, Lancet 1981 1 8218 466 469 10.1016/S0140-6736(81)91850-X 6110091
12. Clinical features of familial hypercholesterolemia. A Yamamoto T Kamiya T Yamamura S Yokoyama Y Horiguchi T Funahashi A Kawaguchi Y Miyake S Beppu K Ishikawa, Arteriosclerosis 1989 9 1 Suppl 66 74 2912433
13. Familial hypercholesterolemia: a genetic receptor disease. JL Goldstein MS Brown, Hosp Pract (Off Ed) 1985 20 11 35 41 45-36 3932389
14. Coronary heart disease risk factors in women. ML Brochier P Arwidson, European heart journal 1998 19 Suppl A 45 52 9519343
15. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. KE Heath M Gahan RA Whittall SE Humphries, Atherosclerosis 2001 154 1 243 246 10.1016/S0021-9150(00)00647-X 11137106
16. A host of hypercholesterolaemic homozygotes in South Africa. HC Seftel SG Baker MP Sandler MB Forman BI Joffe D Mendelsohn T Jenkins CJ Mieny, Br Med J 1980 281 6241 633 636 10.1136/bmj.281.6241.633 7437743
17. The use of low density lipoprotein receptor activity of lymphocytes to determine the prevalence of familial hypercholesterolaemia in a rural South African community. K Steyn MJ Weight BR Dando KJ Christopher JE Rossouw, J Med Genet 1989 26 1 32 36 10.1136/jmg.26.1.32 2918524
18. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. D Marks M Thorogood HA Neil SE Humphries, Atherosclerosis 2003 168 1 1 14 10.1016/S0021-9150(02)00330-1 12732381
19. Lipid metabolism, hyper- and hypolipidaemias and atherosclerosis. C Marenah, Clinical biochemistry: metabolic and clinical aspects Edinburgh,: Churchill Livingstone, Marshall W, Bangert S, 1995 35 621 640
20. The sequence and topology of human complement component C9. KK Stanley HP Kocher JP Luzio P Jackson J Tschopp, Embo J 1985 4 2 375 382 4018030
21. Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor. DW Russell WJ Schneider T Yamamoto KL Luskey MS Brown JL Goldstein, Cell 1984 37 2 577 585 10.1016/0092-8674(84)90388-X 6327078
22. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. JL Goldstein MS Brown RG Anderson DW Russell WJ Schneider, Annu Rev Cell Biol 1985 1 1 39 10.1146/annurev.cb.01.110185.000245 2881559
23. The LDL receptor gene: a mosaic of exons shared with different proteins. TC Sudhof JL Goldstein MS Brown DW Russell, Science 1985 228 4701 815 822 10.1126/science.2988123 2988123
24. Cassette of eight exons shared by genes for LDL receptor and EGF precursor. TC Sudhof DW Russell JL Goldstein MS Brown R Sanchez-Pescador GI Bell, Science 1985 228 4701 893 895 10.1126/science.3873704 3873704
25. Familial hypercholesterolaemia. JL Goldstein HH Hobbs MS Brown, The Metabolic and Molecular Basis of Inherited Diseases New York: McGraw-Hill, Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstien B, 2001 2863 2913
26. Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene. TC Sudhof DR Van der Westhuyzen JL Goldstein MS Brown DW Russell, The Journal of biological chemistry 1987 262 22 10773 10779 3611089
27. Intracellular cholesterol transport. CJ Fielding PE Fielding, Journal of lipid research 1997 38 8 1503 1521 9300773
28. Long-term blood cholesterol-lowering effects of a dietary fiber supplement. RH Knopp HR Superko M Davidson W Insull CA Dujovne PO Kwiterovich JH Zavoral K Graham RR O'Connor DA Edelman, Am J Prev Med 1999 17 1 18 23 10.1016/S0749-3797(99)00039-2 10429748
29. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. RH Knopp CE Walden BM Retzlaff BS McCann AA Dowdy JJ Albers GO Gey MN Cooper, Jama 1997 278 18 1509 1515 10.1001/jama.278.18.1509 9363971
30. Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men. CE Walden BM Retzlaff BL Buck BS McCann RH Knopp, Arteriosclerosis, thrombosis, and vascular biology 1997 17 2 375 382 9081694
31. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone, Circulation 2004 110 2 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516
32. Statins: effective antiatherosclerotic therapy. RS Blumenthal, Am Heart J 2000 139 4 577 583 10.1016/S0002-8703(00)90033-4 10740137
33. Poor adherence with hypolipidemic drugs: a lost opportunity. RT Tsuyuki TJ Bungard, Pharmacotherapy 2001 21 5 576 582 10.1592/phco.21.6.576.34541 11349746
34. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. MH Davidson, The American journal of cardiology 2005 96 9A 3K 13K discussion 34K-35K 10.1016/j.amjcard.2005.08.002 16291008
35. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. MH Davidson MA Dillon B Gordon P Jones J Samuels S Weiss J Isaacsohn P Toth SK Burke, Arch Intern Med 1999 159 16 1893 1900 10.1001/archinte.159.16.1893 10493319
36. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. KG Berge PL Canner, European journal of clinical pharmacology 1991 40 Suppl 1 49 51 10.1007/BF01409409 2044644
37. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. HB Rubins SJ Robins D Collins CL Fye JW Anderson MB Elam FH Faas E Linares EJ Schaefer G Schectman TJ Wilt J Wittes, The New England journal of medicine 1999 341 6 410 418 10.1056/NEJM199908053410604 10438259
38. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. T Sudhop D Lutjohann A Kodal M Igel DL Tribble S Shah I Perevozskaya K von Bergmann, Circulation 2002 106 15 1943 1948 10.1161/01.CIR.0000034044.95911.DC 12370217
39. Management of dyslipidemia in the high-risk patient. EA Stein, Am Heart J 2002 144 6 Suppl 43 50 10.1067/mhj.2002.130302 12486415
40. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. CA Dujovne MP Ettinger JF McNeer LJ Lipka AP LeBeaut R Suresh B Yang EP Veltri, The American journal of cardiology 2002 90 10 1092 1097 10.1016/S0002-9149(02)02798- 4 12423709
41. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. RH Knopp H Gitter T Truitt H Bays CV Manion LJ Lipka AP LeBeaut R Suresh B Yang EP Veltri, European heart journal 2003 24 8 729 741 10.1016/S0195-668X(02)00807-2 12713767
42. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. K Berneis M Rizzo HK Berthold GA Spinas W Krone I Gouni-Berthold, European heart journal 2010 31 13 1633 1639 10.1093/eurheartj/ehq181 20525999
43. Statin and ezetimibe combination therapy in cardiovascular disease. E Dembowski MH Davidson, Current opinion in endocrinology, diabetes, and obesity 2009 16 2 183 188 19262375
44. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. D Hunninghake W Insull Jr P Toth D Davidson JM Donovan SK Burke, Atherosclerosis 2001 158 2 407 416 10.1016/S0021-9150(01) 00437-3 11583720
45. New horizons in combination drug therapy for hypercholesterolemia. DR Illingworth, Cardiology 1989 76 Suppl 1 83 94 discussion 94-100 10.1159/000174550 2653626
46. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. M Denke T Pearson P McBride RA Gazzara WE Brady AM Tershakovec, Diab Vasc Dis Res 2006 3 2 93 102 10.3132/dvdr.2006.020 17058629
47. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. C Gagne D Gaudet E Bruckert, Circulation 2002 105 21 2469 2475 10.1161/01.CIR.0000018744. 58460.62 12034651
48. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. DW Bilheimer JL Goldstein SM Grundy MS Brown, J Clin Invest 1975 56 6 1420 1430 10.1172/JCI108223 172531
49. LDL-apheresis: results of longterm treatment and vascular outcome. C Keller, Atherosclerosis 1991 86 1 1 8 10.1016/0021-9150(91)90093-I 2064631
50. Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia. C Mora JL Teruel JF Navarro, The American journal of cardiology 2001 88 2 202 203 10.1016/S0002-9149(01)01664-2 11463060
51. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. JL Teruel MA Lasuncion JF Navarro P Carrero J Ortuno, Metabolism 1995 44 7 929 933 10.1016/0026-0495(95)90247-3 7616853
52. Recommendations for the use of LDL apheresis. GR Thompson, Atherosclerosis 2008 198 2 247 255 10.1016/j.atherosclerosis.2008.02.009 18371971
53. Efficacy criteria and cholesterol targets for LDL apheresis. GR Thompson M Barbir D Davies P Dobral M Gesinde M Livingston P Mandry AD Marais S Matthews C Neuwirth A Pottle C le Roux D Scullard C Tyler S Watkins, Atherosclerosis 2010 208 2 317 321 10.1016/j.atherosclerosis.2009.06.010 19589528
54. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. DW Bilheimer JL Goldstein SM Grundy TE Starzl MS Brown, The New England journal of medicine 1984 311 26 1658 1664 10.1056/ NEJM198412273112603 6390206
55. Heart-liver transplantation in a patient with familial hypercholesterolaemia. TE Starzl DW Bilheimer HT Bahnson BW Shaw Jr RL Hardesty BP Griffith S Iwatsuki BJ Zitelli JC Gartner Jr JJ Malatack AH Urbach, Lancet 1984 1 8391 1382 1383 10.1016/S0140-6736(84)91876-2 6145836
56. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. JM Hoeg TE Starzl HB Brewer Jr, Am J Cardiol 1987 59 6 705 707 10.1016/0002-9149(87)91199-4 3548303
57. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins. K El Harchaoui F Akdim ES Stroes MD Trip JJ Kastelein, Am J Cardiovasc Drugs 2008 8 4 233 242 10.2165/00129784-200808040-00003 18690757
58. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. D Amin RZ Rutledge SN Needle HF Galczenski K Neuenschwander AC Scotese MP Maguire RC Bush DJ Hele GE Bilder MH Perrone, The Journal of pharmacology and experimental therapeutics 1997 281 2 746 752 9152381
59. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. D Aggarwal KL West TL Zern S Shrestha M Vergara-Jimenez ML Fernandez, BMC cardiovascular disorders 2005 5 30 10.1186/1471-2261-5-30 16188040
60. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. M Cuchel LT Bloedon PO Szapary DM Kolansky ML Wolfe A Sarkis JS Millar K Ikewaki ES Siegelman RE Gregg DJ Rader, The New England journal of medicine 2007 356 2 148 156 10.1056/NEJMoa061189 17215532
61. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. M Frank-Kamenetsky A Grefhorst NN Anderson TS Racie B Bramlage A Akinc D Butler K Charisse R Dorkin Y Fan C Gamba-Vitalo P Hadwiger M Jayaraman M John KN Jayaprakash M Maier L Nechev KG Rajeev T Read I Rohl J Soutschek P Tan J Wong G Wang T Zimmermann A de Fougerolles HP Vornlocher R Langer DG Anderson M Manoharan,, et al. Proceedings of the National Academy of Sciences of the United States of America 2008 105 33 11915 11920 10.1073/pnas.0805434105 18695239
62. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. J Soutschek A Akinc B Bramlage K Charisse R Constien M Donoghue S Elbashir A Geick P Hadwiger J Harborth M John V Kesavan G Lavine RK Pandey T Racie KG Rajeev I Rohl I Toudjarska G Wang S Wuschko D Bumcrot V Koteliansky S Limmer M Manoharan HP Vornlocher, Nature 2004 432 7014 173 178 10.1038/nature03121 15538359
63. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. N Gupta N Fisker MC Asselin M Lindholm C Rosenbohm H Orum J Elmen NG Seidah EM Straarup, PloS one 2010 5 5 10682 10.1371/journal.pone.0010682 20498851
64. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. E Merki MJ Graham AE Mullick ER Miller RM Crooke RE Pitas JL Witztum S Tsimikas, Circulation 2008 118 7 743 753 10.1161/CIRCULATIONAHA.108.786822 18663084
65. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. FJ Raal RD Santos DJ Blom AD Marais MJ Charng WC Cromwell RH Lachmann D Gaudet JL Tan S Chasan-Taber DL Tribble JD Flaim ST Crooke, Lancet 2010 375 9719 998 1006 10.1016/S0140-6736(10)60284-X 20227758
66. The Medical News. http://www.news-medical.net/news/20100805/Genzyme-Isis- announce-results-of-two-mipomersen-phase-3-studies.aspx
67. ClinicalTrials.gov identifier: NCT00281008. http://clinicaltrials.gov/ ct2/show/NCT00281008?term=NCT00281008&rank=1
68. ClinicalTrials.gov identifier: NCT00607373. http://clinicaltrials.gov/ ct2/results?term=NCT00607373
69. ClinicalTrials.gov identifier: NCT00694109. http://clinicaltrials.gov/ ct2/show/NCT00694109
70. ClinicalTrials.gov identifier: NCT00706849. http://clinicaltrials.gov/ ct2/show/study/NCT00706849
71. Gene therapy for human liver disease. SE Raper JM Wilson, Prog Liver Dis 1995 13 201 230 9224503
72. Prospects of therapy of liver diseases with foreign genes. KK Kormis GY Wu, Semin Liver Dis 1995 15 3 257 267 10.1055/s-2007-1007279 7491505
73. The liver as a target for gene therapy. G Cichon M Strauss, Concept in gene therapy Berlin: Walter de Gruyter, Strauss M, Barranger J, 1997 13 267 281
74. A sensitive noninvasive method for monitoring successful liver-directed gene transfer of the low-density lipoprotein receptor in Watanabe hyperlipidemic rabbits in vivo. UJ Tietge G Cichon C Buttner J Genschel J Heeren P Gielow N Grewe M Dogar U Beisiegel MP Manns H Lochs W Burchert HH Schmidt, Gene Ther 2004 11 7 574 580 10.1038/sj.gt.3302206 14724675
75. The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits. An animal model for familial hypercholesterolemia. Y Watanabe T Ito M Shiomi, Atherosclerosis 1985 56 1 71 79 10.1016/0021-9150(85)90085-1 4026937
76. Genetically determined hypercholesterolemia in a rhesus monkey family due to a deficiency of the LDL receptor. AM Scanu A Khalil L Neven M Tidore G Dawson D Pfaffinger E Jackson KD Carey HC McGill GM Fless, J Lipid Res 1988 29 12 1671 1681 3244017
77. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. S Ishibashi JL Goldstein MS Brown J Herz DK Burns, The Journal of clinical investigation 1994 93 5 1885 1893 10.1172/JCI117179 8182121
78. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. T Yamamoto RW Bishop MS Brown JL Goldstein DW Russell, Science (New York, NY) 1986 232 4755 1230 1237 10.1126/science.3010466
79. Kinetic defects in the processing of the low density lipoprotein receptor in fibroblasts from WHHL rabbits and a family with familial hypercholesterolemia. WJ Schneider MS Brown JL Goldstein, Molecular biology & medicine 1983 1 3 353 367
80. The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe. M Shiomi T Ito, Atherosclerosis 2009 207 1 1 7 10.1016/j.atherosclerosis.2009.03.024 19389675
81. Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression. M Nakamuta S Taniguchi BY Ishida K Kobayashi L Chan, Arteriosclerosis, thrombosis, and vascular biology 1998 18 5 747 755 9598833
82. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. LB Agellon A Walsh T Hayek P Moulin XC Jiang SA Shelanski JL Breslow AR Tall, The Journal of biological chemistry 1991 266 17 10796 10801 2040599
83. Methods of gene delivery. NA Wivel JM Wilson, Hematol Oncol Clin North Am 1998 12 3 483 501 10.1016/S0889-8588(05)70004-6 9684094
84. Scope and limitations of gene therapy. DJ Weatherall, Br Med Bull 1995 51 1 1 11 7767636
85. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. S Hacein-Bey-Abina C von Kalle M Schmidt F Le Deist N Wulffraat E McIntyre I Radford JL Villeval CC Fraser M Cavazzana-Calvo A Fischer, The New England journal of medicine 2003 348 3 255 256 10.1056/NEJM200301163480314 12529469
86. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. S Hacein-Bey-Abina C Von Kalle M Schmidt MP McCormack N Wulffraat P Leboulch A Lim CS Osborne R Pawliuk E Morillon R Sorensen A Forster P Fraser JI Cohen G de Saint Basile I Alexander U Wintergerst T Frebourg A Aurias D Stoppa-Lyonnet S Romana I Radford-Weiss F Gross F Valensi E Delabesse E Macintyre F Sigaux J Soulier LE Leiva M Wissler,, et al. Science (New York, NY) 2003 302 5644 415 419 10.1126/science.1088547 (Pubitemid 37296260)
87. Non-viral and hybrid vectors in human gene therapy: an update. GD Schmidt-Wolf IG Schmidt-Wolf, Trends Mol Med 2003 9 2 67 72 10.1016/S1471- 4914(03)00005-4 12615040
88. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. SA Audouy LF de Leij D Hoekstra G Molema, Pharm Res 2002 19 11 1599 1605 10.1023/A:1020989709019 12458664
89. Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. RI Mahato K Kawabata T Nomura Y Takakura M Hashida, J Pharm Sci 1995 84 11 1267 1271 10.1002/jps.2600841102 8587040
90. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. F Liu Y Song D Liu, Gene therapy 1999 6 7 1258 1266 10.1038/sj.gt.3300947 10455434
91. Low-density lipoprotein (LDL) receptor/transferrin fusion protein: in vivo production and functional evaluation as a potential therapeutic tool for lowering plasma LDL cholesterol. G Razzini F Parise D Calebiro R Battini B Bagni T Corazzari P Tarugi C Angelelli S Molinari L Falqui S Ferrari, Human gene therapy 2004 15 6 533 541 10.1089/104303404323141980 15212712
92. Isolation of Chinese hamster cell mutants defective in the receptor-mediated endocytosis of low density lipoprotein. M Krieger MS Brown JL Goldstein, J Mol Biol 1981 150 2 167 184 10.1016/0022-2836(81)90447-2 6275086
93. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. R Wade-Martins Y Saeki EA Chiocca, Mol Ther 2003 7 5 Pt 1 604 612 10.1016/S1525-0016(03)00060-1 12718903
94. An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. MM Lufino R Manservigi R Wade-Martins, Nucleic acids research 2007 35 15 98 10.1093/nar/gkm570 17675302
95. Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. OC Hibbitt RP Harbottle SN Waddington CA Bursill C Coutelle KM Channon R Wade-Martins, The journal of gene medicine 2007 9 6 488 497 10.1002/jgm.1041 17471590
96. Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs. OC Hibbitt E McNeil MM Lufino L Seymour K Channon R Wade-Martins, Mol Ther 2010 18 2 317 326 10.1038/mt.2009.249 19861949
97. Antisense apolipoprotein B therapy: where do we stand? F Akdim ES Stroes JJ Kastelein, Current opinion in lipidology 2007 18 4 397 400 10.1097/MOL.0b013e328248b4ad 17620855
98. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. F Akdim ES Stroes EJ Sijbrands DL Tribble MD Trip JW Jukema JD Flaim J Su R Yu BF Baker MK Wedel JJ Kastelein, Journal of the American College of Cardiology 2010 55 15 1611 1618 10.1016/j.jacc.2009.11.069 20378080
99. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. RM Crooke MJ Graham KM Lemonidis CP Whipple S Koo RJ Perera, Journal of lipid research 2005 46 5 872 884 10.1194/jlr.M400492-JLR200 15716585
100. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense? MK Ito, The Annals of pharmacotherapy 2007 41 10 1669 1678 10.1345/aph.1K065 17848425
101. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. JJ Kastelein MK Wedel BF Baker J Su JD Bradley RZ Yu E Chuang MJ Graham RM Crooke, Circulation 2006 114 16 1729 1735 10.1161/CIRCULATIONAHA. 105.606442 17030687
102. Novel molecules targeting dyslipidemia and atherosclerosis. A Tavridou VG Manolopoulos, Current medicinal chemistry 2008 15 8 792 802 10.2174/092986708783955482 18393849
103. Gene therapy - promises, problems and prospects. IM Verma N Somia, Nature 1997 389 6648 239 242 10.1038/38410 9305836
104. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. WY Chen EC Bailey SL McCune JY Dong TM Townes, Proceedings of the National Academy of Sciences of the United States of America 1997 94 11 5798 5803 10.1073/pnas.94.11.5798 9159154
105. Progress and problems with the use of viral vectors for gene therapy. CE Thomas A Ehrhardt MA Kay, Nat Rev Genet 2003 4 5 346 358 10.1038/nrg1066 12728277
106. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. O Dorigo JS Gil SD Gallaher BT Tan MG Castro PR Lowenstein MP Calos AJ Berk, J Virol 2004 78 12 6556 6566 10.1128/JVI.78.12.6556-6566.2004 15163748
107. Retroviruses. J Coffin SH Hughes HE Varmus, New York: Cold Spring Harbor Laboratory Press First 1997
108. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. R Mann RC Mulligan D Baltimore, Cell 1983 33 1 153 159 10.1016/0092-8674(83)90344-6 6678608
109. Retroviral vectors. WH Gunzburg B Salmons, Gene Therapy Oxford: BIOS Scientific Publishers Limited, Lemoine NR, Cooper DN, First 1996 1 72 102
110. Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. JL Davis RM Witt PR Gross CA Hokanson S Jungles LK Cohen O Danos SK Spratt, Human gene therapy 1997 8 12 1459 1467 10.1089/hum.1997.8.12-1459 9287146
111. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. NJ DePolo CE Harkleroad M Bodner AT Watt CG Anderson JS Greengard KK Murthy TW Dubensky Jr DJ Jolly, J Virol 1999 73 8 6708 6714 10400768
112. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. O Danos RC Mulligan, Proc Natl Acad Sci USA 1988 85 17 6460 6464 10.1073/pnas.85.17.6460 3413107
113. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. JC Burns F T W Driever M Burrascano JK Yee, Proc Natl Acad Sci USA 1993 1;90 17 8033 8037 10.1073/pnas.90.17.8033
114. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. MA Bender TD Palmer RE Gelinas AD Miller, J Virol 1987 61 5 1639 1646 3502707
115. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. SF Yu T von Ruden PW Kantoff C Garber M Seiberg U Ruther WF Anderson EF Wagner E Gilboa, Proc Natl Acad Sci USA 1986 83 10 3194 3198 10.1073/pnas.83.10.3194 3458176
116. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. JR Chowdhury M Grossman S Gupta NR Chowdhury JR Baker Jr JM Wilson, Science (New York, NY) 1991 254 5039 1802 1805 10.1126/science.1722351
117. Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity. M Grossman SE Raper JM Wilson, Human gene therapy 1992 3 5 501 510 10.1089/hum.1992.3.5-501 1420448
118. A novel approach for introducing hepatocytes into the portal circulation. M Grossman JM Wilson SE Raper, J Lab Clin Med 1993 121 3 472 478 8445295
119. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. M Grossman SE Raper K Kozarsky EA Stein JF Engelhardt D Muller PJ Lupien JM Wilson, Nat Genet 1994 6 4 335 341 10.1038/ng0494-335 8054972
120. Gene therapy for cholesterol. MS Brown JL Goldstein RJ Havel D Steinberg, Nature genetics 1994 7 3 349 350 10.1038/ng0794-349 7920651
121. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. M Grossman DJ Rader DW Muller DM Kolansky K Kozarsky BJ Clark EA Stein PJ Lupien HB Brewer Jr SE Raper JM Wilson, Nat Med 1995 1 11 1148 1154 10.1038/nm1195-1148 7584986
122. Adenoviridae, The viruses and their replication. T Shenk, Fields Virology Philadelphia: Lippincott-William and Wilkins, Fields B, Knipe D, Howley P, 4 1999 2 2265 2300
123. Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. K Kozarsky M Grossman JM Wilson, Somatic cell and molecular genetics 1993 19 5 449 458 10.1007/BF01233250 8291022
124. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. KF Kozarsky K Jooss M Donahee JF Strauss JM Wilson, Nat Genet 1996 13 1 54 62 10.1038/ng0596-54 8673104
125. Virus treatment questioned after gene therapy death. S Lehrman, Nature 1999 401 6753 517 518 10.1038/43977 10524611
126. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. JM Bergelson JA Cunningham G Droguett EA Kurt-Jones A Krithivas JS Hong MS Horwitz RL Crowell RW Finberg, Science 1997 275 5304 1320 1323 10.1126/science.275.5304.1320 9036860
127. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. TJ Wickham P Mathias DA Cheresh GR Nemerow, Cell 1993 73 2 309 319 10.1016/0092-8674(93)90231-E 8477447
128. Generation of adenovirus by transfection of plasmids. KL Berkner PA Sharp, Nucleic acids research 1983 11 17 6003 6020 10.1093/nar/11.17.6003 6310523
129. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. S Ishibashi MS Brown JL Goldstein RD Gerard RE Hammer J Herz, J Clin Invest 1993 92 2 883 893 10.1172/JCI116663 8349823 (Pubitemid 23262411)
130. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. KF Kozarsky DR McKinley LL Austin SE Raper LD Stratford-Perricaudet JM Wilson, J Biol Chem 1994 269 18 13695 13702 8175805
131. In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Li B Fang RC Eisensmith XH Li I Nasonkin YC Lin-Lee MP Mims A Hughes CD Montgomery JD Roberts TS Parker DM Levine SL Woo, J Clin Invest 1995 95 2 768 773 10.1172/JCI117725 7860759
132. Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high-density lipoproteins. DR Brown ME Brousseau RD Shamburek GD Talley S Meyn SJ Demosky Jr S Santamarina-Fojo HB Brewer Jr JM Hoeg, Metabolism 1996 45 12 1447 1457 10.1016/S0026-0495(96)90172-9 8969276
133. Nonphysiological overexpression of low-density lipoprotein receptors causes pathological intracellular lipid accumulation and the formation of cholesterol and cholesteryl ester crystals in vitro. J Heeren DS Steinwaerder F Schnieders G Cichon M Strauss U Beisiegel, J Mol Med 1999 77 10 735 743 10.1007/s001099900045 10606209
134. Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage. G Cichon T Willnow S Herwig W Uckert P Loser HH Schmidt T Benhidjeb PM Schlag F Schnieders D Niedzielska J Heeren, The journal of gene medicine 2004 6 2 166 175 10.1002/jgm.473 14978770
135. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Y Dai EM Schwarz D Gu WW Zhang N Sarvetnick IM Verma, Proc Natl Acad Sci USA 1995 92 5 1401 1405 10.1073/pnas.92.5.1401 7877990
136. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. D Barr J Tubb D Ferguson A Scaria A Lieber C Wilson J Perkins MA Kay, Gene Ther 1995 2 2 151 155 7719932
137. Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade. CS Stein I Martins BL Davidson, J Gene Med 2000 2 1 41 51 10.1002/(SICI)1521-2254(200001/02)2:1<41::AID-JGM79>3.0.CO;2-P 10765504
138. Second-generation adenovirus vectors. Q Wang MH Finer, Nature medicine 1996 2 6 714 716 10.1038/nm0696-714 8640568
139. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. S Nomura A Merched E Nour C Dieker K Oka L Chan, Gene therapy 2004 11 20 1540 1548 10.1038/sj.gt.3302310 15269711
140. Adenoviral low density lipoprotein receptor attenuates progression of atherosclerosis and decreases tissue cholesterol levels in a murine model of familial hypercholesterolemia. F Jacobs E Van Craeyveld Y Feng J Snoeys B De Geest, Atherosclerosis 2008 201 2 289 297 10.1016/j.atherosclerosis.2008.02.023 18378244
141. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. K Oka L Pastore IH Kim A Merched S Nomura HJ Lee M Merched-Sauvage C Arden-Riley B Lee M Finegold A Beaudet L Chan, Circulation 2001 103 9 1274 1281 11238273
142. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. JM Isner T Asahara, The Journal of clinical investigation 1999 103 9 1231 1236 10.1172/JCI6889 10225965
143. An update on gene therapy for hemophilia. AC Nathwani J McIntosh AM Davidoff, Curr Hematol Rep 2005 4 4 287 293 16009043
144. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. CS Manno GF Pierce VR Arruda B Glader M Ragni JJ Rasko MC Ozelo K Hoots P Blatt B Konkle M Dake R Kaye M Razavi A Zajko J Zehnder PK Rustagi H Nakai A Chew D Leonard JF Wright RR Lessard JM Sommer M Tigges D Sabatino A Luk H Jiang F Mingozzi L Couto HC Ertl KA High,, et al. Nature medicine 2006 12 3 342 347 10.1038/nm1358 16474400
145. Parvoviridae, The viruses and their replication. N Muzyczka KI Berns, Fields Virology Philadelphia: Lippincott-William and Wilkins, Fields B, Knipe D, Howley P, 4 1999 2 2327 2379
146. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. AM Davidoff JT Gray CY Ng Y Zhang J Zhou Y Spence Y Bakar AC Nathwani, Mol Ther 2005 11 6 875 888 10.1016/j.ymthe.2004.12.022 15922958
147. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. AM Davidoff CY Ng J Zhou Y Spence AC Nathwani, Blood 2003 102 2 480 488 10.1182/blood-2002-09-2889 12637328
148. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. D Duan Y Yue Z Yan J Yang JF Engelhardt, The Journal of clinical investigation 2000 105 11 1573 1587 10.1172/JCI8317 10841516
149. Enhancing transduction of the liver by adeno-associated viral vectors. AC Nathwani M Cochrane J McIntosh CY Ng J Zhou JT Gray AM Davidoff, Gene therapy 2009 16 1 60 69 10.1038/gt.2008.137 18701909
150. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. KJ Fisher GP Gao MD Weitzman R DeMatteo JF Burda JM Wilson, Journal of virology 1996 70 1 520 532 8523565
151. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Z Wang HI Ma J Li L Sun J Zhang X Xiao, Gene therapy 2003 10 26 2105 2111 10.1038/sj.gt.3302133 14625564
152. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. AC Nathwani JT Gray CY Ng J Zhou Y Spence SN Waddington EG Tuddenham G Kemball-Cook J McIntosh M Boon-Spijker K Mertens AM Davidoff, Blood 2006 107 7 2653 2661 10.1182/blood-2005-10-4035 16322469
153. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. SJ Chen DJ Rader J Tazelaar M Kawashiri G Gao JM Wilson, Mol Ther 2000 2 3 256 261 10.1006/mthe.2000.0122 10985956
154. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. C Lebherz G Gao JP Louboutin J Millar D Rader JM Wilson, J Gene Med 2004 6 6 663 672 10.1002/jgm.554 15170737
155. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. GP Gao MR Alvira L Wang R Calcedo J Johnston JM Wilson, Proc Natl Acad Sci USA 2002 99 18 11854 11859 10.1073/pnas.182412299 12192090
156. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. K Kitajima DH Marchadier GC Miller GP Gao JM Wilson DJ Rader, Arteriosclerosis, thrombosis, and vascular biology 2006 26 8 1852 1857 10.1161/01.ATV.0000231520. 26490.54 16763161
157. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Y Liu D Li J Chen J Xie S Bandyopadhyay D Zhang AR Nemarkommula H Liu JL Mehta PL Hermonat, Atherosclerosis 2006 188 1 19 27 10.1016/j.atherosclerosis.2005.10.029 16300768
158. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. T Yoshioka T Okada Y Maeda U Ikeda M Shimpo T Nomoto K Takeuchi M Nonaka-Sarukawa T Ito M Takahashi T Matsushita H Mizukami Y Hanazono A Kume S Ookawara M Kawano S Ishibashi K Shimada K Ozawa, Gene therapy 2004 11 24 1772 1779 10.1038/sj.gt.3302348 15496963
159. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. SH Kassim H Li LH Vandenberghe C Hinderer P Bell D Marchadier A Wilson D Cromley V Redon H Yu JM Wilson DJ Rader, PloS one 2010 5 10 13424 10.1371/journal.pone.0013424 20976059
160. Clinical gene therapy using recombinant adeno-associated virus vectors. C Mueller T Flotte, Gene Ther 2008 15 11 858 863 10.1038/gt.2008.68 18418415
161. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. MA Kay JC Glorioso L Naldini, Nature medicine 2001 7 1 33 40 10.1038/83324 11135613
162. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. JB Rohll KA Mitrophanous E Martin-Rendon FM Ellard PA Radcliffe ND Mazarakis SM Kingsman, Methods Enzymol 2002 346 466 500 full-text 11883086
163. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. MI Bukrinsky S Haggerty MP Dempsey N Sharova A Adzhubel L Spitz P Lewis D Goldfarb M Emerman M Stevenson, Nature 1993 365 6447 666 669 10.1038/365666a0 8105392
164. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. MI Bukrinsky N Sharova TL McDonald T Pushkarskaya WG Tarpley M Stevenson, Proceedings of the National Academy of Sciences of the United States of America 1993 90 13 6125 6129 10.1073/pnas.90.13.6125 7687060
165. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. PF Lewis M Emerman, J Virol 1994 68 1 510 516 8254763
166. Integrase-defective lentiviral vectors: progress and applications. MB Banasik PB McCray Jr, Gene therapy 2010 17 2 150 157 10.1038/gt.2009.135 19847206
167. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. CD Pauza P Trivedi TS McKechnie DD Richman FM Graziano, Virology 1994 205 2 470 478 10.1006/viro.1994.1667 7975248
168. Circularization of human immunodeficiency virus type 1 DNA in vitro. CM Farnet WA Haseltine, Journal of virology 1991 65 12 6942 6952 1834863
169. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. V Baekelandt A Claeys K Eggermont E Lauwers B De Strooper B Nuttin Z Debyser, Hum Gene Ther 2002 13 7 841 853 10.1089/10430340252899019 11975850
170. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. V Baekelandt K Eggermont M Michiels B Nuttin Z Debyser, Gene Ther 2003 10 23 1933 1940 10.1038/sj.gt.3302094 14528317
171. Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. JP O'Rourke H Hiraragi K Urban M Patel JC Olsen BA Bunnell, Mol Ther 2003 7 5 Pt 1 632 639 12718906
172. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. F Park K Ohashi MA Kay, Blood 2000 96 3 1173 1176 10910939
173. Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo. J Zhao GJ Pettigrew J Thomas JI Vandenberg L Delriviere EM Bolton A Carmichael JL Martin MS Marber AM Lever, Basic Res Cardiol 2002 97 5 348 358 10.1007/s00395-002-0360-0 12200634
174. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. S Philippe C Sarkis M Barkats H Mammeri C Ladroue C Petit J Mallet C Serguera, Proceedings of the National Academy of Sciences of the United States of America 2006 103 47 17684 17689 10.1073/pnas.0606197103 17095605
175. Use of nonintegrating lentiviral vectors for gene therapy. NJ Philpott AJ Thrasher, Human gene therapy 2007 18 6 483 489 10.1089/hum.2007.013 17523890
176. Effective gene therapy with nonintegrating lentiviral vectors. RJ Yanez-Munoz KS Balaggan A MacNeil SJ Howe M Schmidt AJ Smith P Buch RE MacLaren PN Anderson SE Barker Y Duran C Bartholomae C von Kalle JR Heckenlively C Kinnon RR Ali AJ Thrasher, Nature medicine 2006 12 3 348 353 10.1038/nm1365 16491086
177. Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation. AC Jenke MF Scinteie IM Stehle HJ Lipps, Molecular biology reports 2004 31 2 85 90 10.1023/B:MOLE. 0000031363.35839.46 15293783
178. Integration-deficient lentiviral vectors: a slow coming of age. K Wanisch RJ Yanez-Munoz, Mol Ther 2009 17 8 1316 1332 10.1038/mt.2009.122 19491821
179. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. AA Rahim AM Wong SJ Howe SM Buckley AD Acosta-Saltos KE Elston NJ Ward NJ Philpott JD Cooper PN Anderson SN Waddington AJ Thrasher G Raivich, Gene therapy 2009 16 4 509 520 10.1038/gt.2008.186 19158847
180. Stable gene transfer to muscle using non-integrating lentiviral vectors. L Apolonia SN Waddington C Fernandes NJ Ward G Bouma MP Blundell AJ Thrasher MK Collins NJ Philpott, Mol Ther 2007 15 11 1947 1954 10.1038/sj.mt.6300281 17700544
181. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. M Bayer B Kantor A Cockrell H Ma B Zeithaml X Li T McCown T Kafri, Mol Ther 2008 16 12 1968 1976 10.1038/mt.2008.199 18797449
182. Construction and analyses of EIAV-based Lentivirus vectors for fetal gene therapy of familial hypercholesterolaemia and haemophilia-B. F Al-Allaf, London: Imperial College Faculty of Medicine, University of London 2004
183. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. L Wang K Takabe SM Bidlingmaier CR Ill IM Verma, Proceedings of the National Academy of Sciences of the United States of America 1999 96 7 3906 3910 10.1073/pnas.96.7.3906 10097136
184. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. HM Kankkonen E Vahakangas RA Marr T Pakkanen A Laurema P Leppanen J Jalkanen IM Verma S Yla-Herttuala, Mol Ther 2004 9 4 548 556 10.1016/j.ymthe.2004.01.015 15093185
185. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. RS Mitchell BF Beitzel AR Schroder P Shinn H Chen CC Berry JR Ecker FD Bushman, PLoS biology 2004 2 8 234 10.1371/journal.pbio.0020234 15314653
186. Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. H Rohdewohld H Weiher W Reik R Jaenisch M Breindl, Journal of virology 1987 61 2 336 343 3027365
187. Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA. HE Varmus T Padgett S Heasley G Simon JM Bishop, Cell 1977 11 2 307 319 10.1016/0092-8674(77)90047-2 196759
188. Transcription start regions in the human genome are favored targets for MLV integration. X Wu Y Li B Crise SM Burgess, Science (New York, NY) 2003 300 5626 1749 1751 10.1126/science.1083413 (Pubitemid 36712571)
189. Lentiviral vector integration sites in human NOD/SCID repopulating cells. S Laufs G Guenechea A Gonzalez-Murillo K Zsuzsanna Nagy M Luz Lozano C del Val S Jonnakuty A Hotz-Wagenblatt W Jens Zeller JA Bueren S Fruehauf, The journal of gene medicine 2006 8 10 1197 1207 10.1002/jgm.958 16960916
190. HIV-1 integration in the human genome favors active genes and local hotspots. AR Schroder P Shinn H Chen C Berry JR Ecker F Bushman, Cell 2002 110 4 521 529 10.1016/S0092-8674(02)00864-4 12202041
191. Insertional inactivation of the tk locus in a human B lymphoblastoid cell line by a retroviral shuttle vector. AJ Grosovsky A Skandalis L Hasegawa BN Walter, Mutation research 1993 289 2 297 308 7690899
192. Insertion mutagenesis of embryonal carcinoma cells by retroviruses. W King MD Patel LI Lobel SP Goff MC Nguyen-Huu, Science (New York, NY) 1985 228 4699 554 558 10.1126/science.3838595
193. Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. C Stocking U Bergholz J Friel K Klingler T Wagener C Starke T Kitamura A Miyajima W Ostertag, Growth factors (Chur, Switzerland) 1993 8 3 197 209 10.3109/08977199309011023 8391284
194. Mutational effects of retrovirus insertion on the genome of V79 cells by an attenuated retrovirus vector: implications for gene therapy. M Themis D May C Coutelle RF Newbold, Gene therapy 2003 10 19 1703 1711 10.1038/sj.gt.3302059 12923569
195. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. M Cavazzana-Calvo S Hacein-Bey G de Saint Basile F Gross E Yvon P Nusbaum F Selz C Hue S Certain JL Casanova P Bousso FL Deist A Fischer, Science (New York, NY) 2000 288 5466 669 672 10.1126/science.288.5466.669 (Pubitemid 30241569)
196. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. S Hacein-Bey-Abina A Garrigue GP Wang J Soulier A Lim E Morillon E Clappier L Caccavelli E Delabesse K Beldjord V Asnafi E MacIntyre L Dal Cortivo I Radford N Brousse F Sigaux D Moshous J Hauer A Borkhardt BH Belohradsky U Wintergerst MC Velez L Leiva R Sorensen N Wulffraat S Blanche FD Bushman A Fischer M Cavazzana-Calvo, The Journal of clinical investigation 2008 118 9 3132 3142 10.1172/JCI35700 18688285
197. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. S Hacein-Bey-Abina F Le Deist F Carlier C Bouneaud C Hue JP De Villartay AJ Thrasher N Wulffraat R Sorensen S Dupuis-Girod A Fischer EG Davies W Kuis L Leiva M Cavazzana-Calvo, The New England journal of medicine 2002 346 16 1185 1193 10.1056/NEJMoa012616 11961146 (Pubitemid 34984579)
198. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. SJ Howe MR Mansour K Schwarzwaelder C Bartholomae M Hubank H Kempski MH Brugman K Pike-Overzet SJ Chatters D de Ridder KC Gilmour S Adams SI Thornhill KL Parsley FJ Staal RE Gale DC Linch J Bayford L Brown M Quaye C Kinnon P Ancliff DK Webb M Schmidt C von Kalle HB Gaspar AJ Thrasher, The Journal of clinical investigation 2008 118 9 3143 3150 10.1172/JCI35798 18688286
199. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. MG Ott M Schmidt K Schwarzwaelder S Stein U Siler U Koehl H Glimm K Kuhlcke A Schilz H Kunkel S Naundorf A Brinkmann A Deichmann M Fischer C Ball I Pilz C Dunbar Y Du NA Jenkins NG Copeland U Luthi M Hassan AJ Thrasher D Hoelzer C von Kalle R Seger M Grez, Nature medicine 2006 12 4 401 409 10.1038/nm1393 16582916
200. Ten years of gene therapy for primary immune deficiencies. A Aiuti MG Roncarolo, Hematology/the Education Program of the American Society of Hematology American Society of Hematology 2009 682 689
201. Side effects of retroviral gene transfer into hematopoietic stem cells. C Baum J Dullmann Z Li B Fehse J Meyer DA Williams C von Kalle, Blood 2003 101 6 2099 2114 10.1182/blood-2002-07-2314 12511419 (Pubitemid 36302043)
202. Murine leukemia induced by retroviral gene marking. Z Li J Dullmann B Schiedlmeier M Schmidt C von Kalle J Meyer M Forster C Stocking A Wahlers O Frank W Ostertag K Kuhlcke HG Eckert B Fehse C Baum, Science (New York, NY) 2002 296 5567 497 10.1126/science.1068893 (Pubitemid 34408663)
203. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. U Modlich OS Kustikova M Schmidt C Rudolph J Meyer Z Li K Kamino N von Neuhoff B Schlegelberger K Kuehlcke KD Bunting S Schmidt A Deichmann C von Kalle B Fehse C Baum, Blood 2005 105 11 4235 4246 10.1182/blood-2004-11-4535 15713797
204. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. E Montini D Cesana M Schmidt F Sanvito M Ponzoni C Bartholomae L Sergi Sergi F Benedicenti A Ambrosi C Di Serio C Doglioni C von Kalle L Naldini, Nature biotechnology 2006 24 6 687 696 10.1038/nbt1216 16732270
205. Genotoxicity of retroviral integration in hematopoietic cells. AW Nienhuis CE Dunbar BP Sorrentino, Mol Ther 2006 13 6 1031 1049 10.1016/j.ymthe.2006.03.001 16624621
206. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. C Baum C von Kalle FJ Staal Z Li B Fehse M Schmidt F Weerkamp S Karlsson G Wagemaker DA Williams, Mol Ther 2004 9 1 5 13 10.1016/j.ymthe.2003. 10.013 14741772
207. Physiological promoters reduce the genotoxic risk of integrating gene vectors. D Zychlinski A Schambach U Modlich T Maetzig J Meyer E Grassman A Mishra C Baum, Mol Ther 2008 16 4 718 725 10.1038/mt.2008.5 18334985
208. Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. SN Waddington KA Mitrophanous FM Ellard SM Buckley M Nivsarkar L Lawrence HT Cook F Al-Allaf B Bigger SM Kingsman C Coutelle M Themis, Gene therapy 2003 10 15 1234 1240 10.1038/sj.gt.3301991 12858188
209. Permanent phenotypic correction of Hemophilia B in immunocompetent mice by prenatal gene therapy. SN Waddington MS Nivsarkar AR Mistry SM Buckley G Kemball-Cook KL Mosley K Mitrophanous P Radcliffe MV Holder M Brittan A Georgiadis F Al-Allaf BW Bigger LG Gregory HT Cook RR Ali A Thrasher EG Tuddenham M Themis C Coutelle, Blood 2004 104 9 2714 2721 10.1182/blood-2004-02- 0627 15231566
210. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. M Themis SN Waddington M Schmidt C von Kalle Y Wang F Al-Allaf LG Gregory M Nivsarkar M Themis MV Holder SM Buckley N Dighe AT Ruthe A Mistry B Bigger A Rahim TH Nguyen D Trono AJ Thrasher C Coutelle, Mol Ther 2005 12 4 763 771 10.1016/j.ymthe.2005.07.358 16084128
211. Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. B Khoo X Roca SL Chew AR Krainer, BMC molecular biology 2007 8 3 10.1186/1471-2199-8-3 17233885
212. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. S Laufs B Gentner KZ Nagy A Jauch A Benner S Naundorf K Kuehlcke B Schiedlmeier AD Ho WJ Zeller S Fruehauf, Blood 2003 101 6 2191 2198 10.1182/blood-2002-02-0627 12424203
213. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. S Laufs KZ Nagy FA Giordano A Hotz-Wagenblatt WJ Zeller S Fruehauf, Mol Ther 2004 10 5 874 881 10.1016/j.ymthe.2004.08.001 15509505
214. Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. J Schuettrumpf JH Liu LB Couto K Addya DG Leonard Z Zhen J Sommer VR Arruda, Mol Ther 2006 13 6 1064 1073 10.1016/j.ymthe.2006.03.002 16631412
215. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. CS Manno AJ Chew S Hutchison PJ Larson RW Herzog VR Arruda SJ Tai MV Ragni A Thompson M Ozelo LB Couto DG Leonard FA Johnson A McClelland C Scallan E Skarsgard AW Flake MA Kay KA High B Glader, Blood 2003 101 8 2963 2972 10.1182/blood-2002-10-3296 12515715
216. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. K Kobayashi K Oka T Forte B Ishida B Teng K Ishimura-Oka M Nakamuta L Chan, The Journal of biological chemistry 1996 271 12 6852 6860 10.1074/jbc.271.12.6852 8636110
217. Very-low-density lipoprotein receptor fragment shed from HeLa cells inhibits human rhinovirus infection. TC Marlovits C Abrahamsberg D Blaas, Journal of virology 1998 72 12 10246 10250 9811769 (Pubitemid 28520899)
218. Recent Advances in Lentiviral Vector Development and Applications. J Matri M Chuah T VandenDriessche, Mol Ther 2010 18 5 477 490 10.1038/mt.2009.319 20087315